Sandoz launches oncology generic gefitinib in 13 EU countries
The medicine will become available immediately in 13 countries across Europe on the day the reference medicine loses market exclusivity. Sandoz will continue to expand to other countries
France-based biopharmaceutical company Osivax has entered into an exclusive license option agreement with Japanese vaccine manufacturer KM Biologics for a broad-spectrum “universal” influenza vaccine candidates in Japan.
VE416 is Vedanta Biosciences’ live biotherapeutic product candidate being developed for treatment of food allergies, including persistent peanut allergy. The study, which is being conducted at MassGeneral Hospital
Neratinib was originally approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer,